Table 3.
Mean A1c Months at complication development by diabetes duration in the EDC 1965–1980 diabetes diagnosis subcohort
| Type 1 diabetes duration at baseline (years) | ||||
|---|---|---|---|---|
| <12 | 12–16 | ≥17 | P value | |
| Microalbuminuria | n at risk = 106 | n at risk = 69 | n at risk = 59 | |
| 759 ± 339 (43) | 879 ± 530 (29) | 941 ± 404 (27) | 0.19 | |
| Proliferative retinopathy | n at risk = 132 | n at risk = 118 | n at risk = 97 | |
| 885 ± 353 (62) | 858 ± 355 (68) | 984 ± 434 (62) | 0.15 | |
| CAD | n at risk = 134 | n at risk = 138 | n at risk = 141 | |
| 897 ± 431 (19) | 1,091 ± 517 (30) | 1,119 ± 446 (49) | 0.21 | |
| CDSP | n at risk = 123 | n at risk = 116 | n at risk = 86 | |
| 993 ± 477 (38) | 922 ± 467 (50) | 987 ± 383 (39) | 0.70 | |
| Overt nephropathy | n at risk = 124 | n at risk = 99 | n at risk = 91 | |
| 1,071 ± 550 (27) | 1,114 ± 554 (20) | 1,309 ± 486 (14) | 0.40 | |
| ESRD | n at risk = 139 | n at risk = 144 | n at risk = 146 | |
| 1,217 ± 463 (16) | 1,259 ± 516 (16) | 1,264 ± 525 (21) | 0.99 | |
Values are mean ± SD (number of cases). Prevalent cases of each complication at baseline were excluded from the respective analysis.